pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Definium shares new psychedelics data and court reprieve for international researchers discussed on The Readout LOUD

Sep 17, 2026·read at STAT ↗Neutral

The latest episode of STAT's "The Readout LOUD" podcast covered two timely topics: Definium's recently released psychedelics data and a court decision that gave international scientists a brief legal reprieve.

Definium presented early findings from its psychedelic program, highlighting promising signals but noting that the data are still early and will require further validation before any regulatory steps.

The court ruling temporarily eases restrictions on foreign researchers working in the United States, a move welcomed by many in the scientific community who fear talent loss to other countries.

The hosts debated how the legal relief might affect the pipeline of U.S. medical research, suggesting that continued uncertainty could still drive some scientists to seek opportunities abroad.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Definium’s new psychedelics data, and a reprieve for international scientists”

read at STAT ↗
554 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVARTISNOVONovo Nordisk Inc
drugs
Obesity2
topics
Obesity2CardiologyGLP-1 receptor

related stories

  • 3h agoNovo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugsBioSpace
  • 1d agoFDA clears first generic radioligand drug; Sionna turns to layoffsBioPharma Dive
  • Sep 10Why two promising heart drugs flopped and what’s nextSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 2d agoNovo walks away from $285M pact to develop monthly GLP-1 obesity drug with AscendisFierce Biotech